Cardiology

AAS use may cause persistent coronary microvascular dysfunction, even years after cessation, highlighting long-term cardiovascular risks.

Aficamten improves symptoms, biomarkers, and quality of life in nonobstructive hypertrophic cardiomyopathy, promising better treatment options.

Exploring how cardiovascular imaging can better address the unique risks and outcomes of heart disease in women.

Plozasiran significantly reduced triglycerides by 57% in severe hypertriglyceridemia, showing promise as a new treatment option.

New triple single-pill treatment lowers BP effectively and safely, simplifying early hypertension management in clinical practice.

Using heart age to guide treatment decisions could lead to inappropriate care, impacting both younger and older patients.

NT-proBNP strongly predicts atrial fibrillation risk, particularly in older adults, with implications for improved risk stratification.

Cardiac MRI reveals key risk factors for sudden cardiac events in Fontan patients, potentially guiding better clinical care.